News & Events

HTG Molecular Diagnostics and Instituto Valenciano de Oncología Initiate Breast Cancer Recurrence Risk Collaboration

TUCSON, Ariz., April 24, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced that it has entered into a research collaboration agreement with Instituto Valenciano de Oncología (IVO).  The initial project, utilizing the HTG EdgeSeq Oncology Biomarker Panel, will focus on the development and validation of a breast cancer recurrence risk score, based on genes that are differentially expressed between patients with low and high risk of recurrence.

full press release

Posted on:

Return To List

Page last updated December 20, 2017